Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA and TAMPA, FL – May 2, 2024 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results • First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023. • In the first quarter of 2024, our gross margin in ...

ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. "We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries," said Karen Zaderej, chairman, CEO, and president ...

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may ...

AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript March 5, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Chris Pasquale - Nephron Mike Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Dave Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Confere ...

Table of Content . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Companies displaying incessant earnings growth will continue to captivate almost everyone in the investment world, from top brass to research analysts. This is because earnings are a measure of the money a company is making. Still, earnings acceleration works better when lifting the stock price.Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in the stock price. Some of the notable companies to have witnessed solid earnings acceleration as of now are Prot ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Company Performance - AxoGen (AXGN) shares have increased by 8.8% over the past month and reached a new 52-week high of $10.65, with a year-to-date gain of 51.8% compared to 7.9% for the Zacks Medical sector and 6.3% for the Zacks Medical - Instruments industry [1] - The company has consistently exceeded earnings expectations, reporting EPS of $0.01 against a consensus estimate of $-0.08 in its last earnings report on November 7, 2023 [2] Financial Projections - For the current fiscal year, AxoGen is projected to earn $0.03 per share on revenues of $158.8 million, with a year-over-year earnings growth of 118.75% [2] - For the next fiscal year, earnings are expected to rise to $0.17 per share on revenues of $178.5 million, representing a year-over-year change of 12.41% [2] Valuation Metrics - AxoGen's current trading valuation is at 345.7X current fiscal year EPS estimates, significantly higher than the peer industry average of 27.9X [4] - On a trailing cash flow basis, the stock trades at 5X compared to the peer group's average of 13.1X, indicating a less favorable value perspective [4] Zacks Rank and Style Scores - AxoGen holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, suggesting potential for future growth [5] - The company has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [3] Industry Comparison - Artivion, Inc. (AORT), a peer in the industry, has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 184.62% [6] - The Medical - Instruments industry is positioned in the top 38% of all industries, indicating favorable conditions for both AxoGen and Artivion [6]

Earnings growth captivates almost everyone, from the top brass to research analysts. After all, earnings are a measure of the money a company is making.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in their price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-over-quarter earnings grow ...

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference ca ...